Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Current Liabilities: 2013-2024

Historic Total Current Liabilities for Ocular Therapeutix (OCUL) over the last 12 years, with Dec 2024 value amounting to $41.4 million.

  • Ocular Therapeutix's Total Current Liabilities rose 35.58% to $49.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.3 million, marking a year-over-year increase of 35.58%. This contributed to the annual value of $41.4 million for FY2024, which is 18.51% up from last year.
  • According to the latest figures from FY2024, Ocular Therapeutix's Total Current Liabilities is $41.4 million, which was up 18.51% from $34.9 million recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's Total Current Liabilities ranged from a high of $41.4 million in FY2024 and a low of $26.3 million during FY2021.
  • For the 3-year period, Ocular Therapeutix's Total Current Liabilities averaged around $35.9 million, with its median value being $34.9 million (2023).
  • Per our database at Business Quant, Ocular Therapeutix's Total Current Liabilities surged by 121.66% in 2020 and then decreased by 1.23% in 2021.
  • Ocular Therapeutix's Total Current Liabilities (Yearly) stood at $26.7 million in 2020, then fell by 1.23% to $26.3 million in 2021, then rose by 19.20% to $31.4 million in 2022, then climbed by 11.15% to $34.9 million in 2023, then grew by 18.51% to $41.4 million in 2024.